The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

Fatty liver disease occurs when more than 5-10% of the liver's weight is made up of fat. This can lead to inflammation in the ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Biomea Fusion (NASDAQ:BMEA – Get Free Report) are both small-cap ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) is expected to issue its quarterly earnings data before the market ...

Theratechnologies Inc.’s THTX share price has surged by 20.78%, which has investors questioning if this is right time to sell ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...